TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Note Receivable - Schedule of Cash Flow in Note Receivable (Details) (Chubeworkx Guernsey Limited [Member], USD $)	Dec. 31, 2014
Principal	$ 1,475,766us-gaap_NotesReceivableRelatedParties
Interest	188,272us-gaap_InterestReceivable
Total	1,664,038
Next 12 Months [Member]
Principal	266,457
Interest	66,350
Total	332,807
Next 13-24 Months [Member]
Principal	280,090
Interest	52,718
Total	332,808
Next 25-36 Months [Member]
Principal	294,420
Interest	38,388
Total	332,808
Next 37-48 Months [Member]
Principal	309,483
Interest	23,325
Total	332,808
Next 49-60 Months [Member]
Principal	325,316
Interest	7,491
Total	$ 332,807

For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.